FOLH1 and prostate carcinoma: In 2022, Morris et al. compared the performance of 89Zr‐df‐IAB2M, an 89Zr‐labeled anti‐PSMA minibody, and 68Ga‐PSMA‐11, a 68Ga‐labeled PSMA small molecule ligand, for PET imaging of localized prostate cancer, and correlated the results with multiparametric MRI.